Literature DB >> 16278727

Angiotensin II receptor blockers.

Amy Barreras1, Cheryle Gurk-Turner.   

Abstract

Year:  2003        PMID： 16278727      PMCID： PMC1200815          DOI： 10.1080/08998280.2003.11927893

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN： 0899-8280


× No keyword cloud information.
  11 in total

Review 1.  Angiotensin II type 1 receptor blockers.

Authors:  M Burnier
Journal:  Circulation       Date:  2001-02-13       Impact factor: 29.690

2.  A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II.

Authors:  D G Vidt; W B White; E Ridley; M Rahman; S Harris; J Vendetti; E L Michelson; R Wang
Journal:  J Hum Hypertens       Date:  2001-07       Impact factor: 3.012

Review 3.  Angiotensin II-receptor blockers: clinical relevance and therapeutic role.

Authors:  J E Rodgers; J H Patterson
Journal:  Am J Health Syst Pharm       Date:  2001-04-15       Impact factor: 2.637

4.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

Authors:  J N Cohn; G Tognoni
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

5.  Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators.

Authors:  K Kassler-Taub; T Littlejohn; W Elliott; T Ruddy; E Adler
Journal:  Am J Hypertens       Date:  1998-04       Impact factor: 2.689

6.  A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators.

Authors:  Y Lacourcière; R Asmar
Journal:  Am J Hypertens       Date:  1999-12       Impact factor: 2.689

7.  A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension.

Authors:  T Hedner; S Oparil; K Rasmussen; A Rapelli; M Gatlin; P Kobi; J Sullivan; P Oddou-Stock
Journal:  Am J Hypertens       Date:  1999-04       Impact factor: 2.689

Review 8.  Angiotensin II receptor antagonists.

Authors:  M Burnier; H R Brunner
Journal:  Lancet       Date:  2000-02-19       Impact factor: 79.321

9.  Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.

Authors:  S Oparil; D Williams; S G Chrysant; T C Marbury; J Neutel
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Sep-Oct       Impact factor: 3.738

10.  ELITE II and Val-HeFT are different trials: together what do they tell us?

Authors:  Kenneth Dickstein
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001
View more
  39 in total

Review 1.  Lessons learned from the ONTARGET and TRANSCEND trials.

Authors:  Jan Basile
Journal:  Curr Atheroscler Rep       Date:  2009-09       Impact factor: 5.113

Review 2.  The Pharmacogenomic and Metabolomic Predictors of ACE Inhibitor and Angiotensin II Receptor Blocker Effectiveness and Safety.

Authors:  Hania K Flaten; Andrew A Monte
Journal:  Cardiovasc Drugs Ther       Date:  2017-08       Impact factor: 3.727

Review 3.  Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?

Authors:  Ali Nehme; Kazem Zibara
Journal:  Hypertens Res       Date:  2017-07-06       Impact factor: 3.872

Review 4.  Telmisartan: a review of its use in cardiovascular disease prevention.

Authors:  James E Frampton
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

Review 5.  Homocysteine and hydrogen sulfide in epigenetic, metabolic and microbiota related renovascular hypertension.

Authors:  Gregory J Weber; Sathnur Pushpakumar; Suresh C Tyagi; Utpal Sen
Journal:  Pharmacol Res       Date:  2016-09-04       Impact factor: 7.658

6.  Cardiac Arrest during Total Hip Arthroplasty in a Patient on an Angiotensin Receptor Antagonist.

Authors:  Susan M Goodman; Daniel Krauser; C Ronald Mackenzie; Stavros Memtsoudis
Journal:  HSS J       Date:  2012-05-11

Review 7.  Can BDDCS illuminate targets in drug design?

Authors:  Giovanni Bocci; Leslie Z Benet; Tudor I Oprea
Journal:  Drug Discov Today       Date:  2019-10-01       Impact factor: 7.851

8.  Does consumption of an aqueous extract of Hibscus sabdariffa affect renal function in subjects with mild to moderate hypertension?

Authors:  Daniel Chukwu Nwachukwu; Eddy Ikemefuna Aneke; Nkiru Zuada Nwachukwu; Nkiru Azubike; Lenard Fidelis Obika
Journal:  J Physiol Sci       Date:  2016-05-24       Impact factor: 2.781

9.  Divergent Spatiotemporal Interaction of Angiotensin Receptor Blocking Drugs with Angiotensin Type 1 Receptor.

Authors:  Khuraijam Dhanachandra Singh; Hamiyet Unal; Russell Desnoyer; Sadashiva S Karnik
Journal:  J Chem Inf Model       Date:  2017-12-27       Impact factor: 4.956

Review 10.  Cardiovascular drugs in the treatment of infantile hemangioma.

Authors:  Israel Fernandez-Pineda; Regan Williams; Lucia Ortega-Laureano; Ryan Jones
Journal:  World J Cardiol       Date:  2016-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.